Search
Crinetics Pharmaceuticals Inc
CRNXAdd to Watchlist
35.870USD
+0.120+0.34%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.78BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Crinetics Pharmaceuticals Inc is 8.50, ranking 106 out of 389 in the Biotechnology & Medical Research industry. The average price target is 83.00, with a high of 108.00 and a low of 45.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
82.615
Target Price
+131.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Crinetics Pharmaceuticals Inc
CRNX
16
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Crinetics Pharmaceuticals Inc's expected revenue for the next quarter?
Crinetics Pharmaceuticals Inc's expected revenue is 14.82M.
What is Crinetics Pharmaceuticals Inc's price target?
Analysts forecast that Crinetics Pharmaceuticals Inc's price target is USD 83.00, with the highest forecast at USD 108.00 and the lowest forecast at USD 45.00.
How have Crinetics Pharmaceuticals IncCRNX's recent earnings per share performed?
The market expectation was USD -1.23, while Crinetics Pharmaceuticals IncCRNX's earnings per share (EPS) for the previous quarter was USD -1.29. EPS for the next quarter is expected at USD -1.23.
What is the analyst rating for Crinetics Pharmaceuticals Inc?
Based on the ratings of Crinetics Pharmaceuticals Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
